Rapid uptake of new oral anticoagulants in the United States
Source: Yale Rosen / Wikimedia Commons
Since 2010, four new direct oral anticoagulant drugs (DOACs, also known as NOACs) — dabigatran, rivaroxaban, apixaban and edoxaban — have been introduced into US clinical practice. To assess their uptake, researchers analysed data from a nationally representative audit of physician visits.
Between 2009 and 2014, visits in which patients were using an oral anticoagulant rose from 2.05 million to 2.83 million per quarter (P<0.001), with DOACs accounting for 38.2% of the total in 2014. Visits involving patients with atrial fibrillation using anticoagulants rose from 51.9% in 2009 to 66.9% in 2014. In 2014, rivaroxaban was the most commonly prescribed DOAC for atrial fibrillation (47.9% of total visits), followed by apixaban (26.5%) and dabigatran (25.5%). Edoxaban had not yet been introduced.
DOACs have been rapidly adopted and have contributed to an increase in atrial fibrillation patients treated with anticoagulants, conclude the authors in The American Journal of Medicine (online, 2 July 2015).
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069088
Recommended from Pharmaceutical Press
This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.£57.00Buy now